Ascendis Pharma Files March 2025 6-K Report
Ticker: ASND · Form: 6-K · Filed: Mar 31, 2025 · CIK: 1612042
Sentiment: neutral
Topics: sec-filing, 6-k, routine-filing
TL;DR
Ascendis Pharma filed a routine 6-K for March 2025, no major news.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on March 31, 2025, for the month of March 2025. This report is a routine filing for foreign private issuers and does not contain specific financial or operational updates beyond its incorporation by reference into existing registration statements on Form S-8.
Why It Matters
This filing serves as a notification to the SEC and investors about the company's ongoing reporting obligations as a foreign private issuer, ensuring transparency.
Risk Assessment
Risk Level: low — This is a standard, routine filing with no new material information or significant financial events disclosed.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- 001-36815 (company) — SEC File Number
- 333-203040 (company) — Form S-8 Registration Number
- 333-210810 (company) — Form S-8 Registration Number
- 333-211512 (company) — Form S-8 Registration Number
- 333-213412 (company) — Form S-8 Registration Number
- 333-214843 (company) — Form S-8 Registration Number
- 333-216883 (company) — Form S-8 Registration Number
- 333-228576 (company) — Form S-8 Registration Number
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a report of foreign private issuer pursuant to Section 13a-16 or 15d-16 under the Securities Exchange Act of 1934, filed for the month of March 2025.
What is the filing date of this report?
The filing date is March 31, 2025.
What is the company's principal executive office address?
The address is Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
Does Ascendis Pharma file annual reports under Form 20-F or 40-F?
Ascendis Pharma indicates it files annual reports under Form 20-F.
What registration statements does this filing incorporate by reference?
This report is incorporated by reference into registration statements on Form S-8, including Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, and 333-228576.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 31, 2025 regarding Ascendis Pharma A/S (ASND).